Bio-Thera Solutions, Ltd.,
Z6·尊龙凯时「中国」官方网站
About Us
Company Overview
Company Culture
Products
QLETLI®
POBEVCY®
TOFIDENCE™
BETAGRIN®
Pipeline
Pipeline
Platforms
R&D Platform
Process & Manufacture
Partnerships
Our Partners
Investors
Company Announcements
Financial Announcements
Contact Information
Media
Press Release
Media Reports
Contact Us
Contact Information
Open Search
Search
中
EN
Location:
Home
>
English site
>
Media
>
Press Release
Press Release
Press Release
Media Reports
Poster: Bio-Thera Solutions Presents Clinical Data for multiple products at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Date: 2025-06-04
Click:
Download Poster_Safety and efficacy of BAT8006, a folate receptor α (FRα) antibody drug conjugate, in patients with platinum-resistant ovarian cancer: Update on the dose optimization/expansion cohort of BAT-8006-001-CR trial.
Download Poster_BAT8008, a Trop-2 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1 study.
Download Poster_A phase Ⅰb/Ⅱa study of BAT8010+BAT1006, an anti-HER2 monoclonal antibody-exatecan conjugate combined with an ADCC-enhanced HER2 mAb in patients with advanced solid tumors.
Download Poster_Primary efficacy and safety results of BAT1308, a PD-1 inhibitor, + chemotherapy ± bevacizumab in phase 2 trial for persistent, recurrent, or metastatic cervical cancer.
Prev:No records
Next:
Bio-Thera Solutions and Hikma Pharmaceuticals Announce FDA Approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
About Us
Company Overview
Company Culture
Products
QLETLI®
POBEVCY®
TOFIDENCE™
BETAGRIN®
Platforms
R&D Platform
Process & Manufacture
Partnerships
Our Partners
Investors
Company Announcements
Financial Announcements
Contact Information
Media
Press Release
Media Reports
Contact Us
Contact Information
WeChat
© 2019 Z6·尊龙凯时生物制药股份有限公司 All Rights Reserved. Designed by Wanhu
粤ICP备17106513号
Legal Notices
Sitemap
Links
Contact Information